Market closed
Haemonetics/$HAE
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Haemonetics
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
Ticker
$HAE
Sector
Trading on
NYSE
Industry
Health Care Equipment & Supplies
Headquarters
Employees
3,657
Website
Haemonetics Metrics
BasicAdvanced
$3.6B
29.58
$2.41
0.32
-
Price and volume
Market cap
$3.6B
Beta
0.32
52-week high
$97.97
52-week low
$69.29
Average daily volume
531K
Financial strength
Current ratio
3.489
Quick ratio
1.875
Long term debt to equity
149.005
Total debt to equity
149.624
Interest coverage (TTM)
14.89%
Management effectiveness
Return on assets (TTM)
6.41%
Return on equity (TTM)
13.97%
Valuation
Price to earnings (TTM)
29.58
Price to revenue (TTM)
2.663
Price to book
4.09
Price to tangible book (TTM)
-15.95
Price to free cash flow (TTM)
116.482
Growth
Revenue change (TTM)
9.84%
Earnings per share change (TTM)
-3.24%
3-year revenue growth (CAGR)
13.38%
3-year earnings per share growth (CAGR)
58.80%
What the Analysts think about Haemonetics
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Haemonetics stock.
Haemonetics Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Haemonetics Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Haemonetics stock?
Haemonetics (HAE) has a market cap of $3.6B as of January 29, 2025.
What is the P/E ratio for Haemonetics stock?
The price to earnings (P/E) ratio for Haemonetics (HAE) stock is 29.58 as of January 29, 2025.
Does Haemonetics stock pay dividends?
No, Haemonetics (HAE) stock does not pay dividends to its shareholders as of January 29, 2025.
When is the next Haemonetics dividend payment date?
Haemonetics (HAE) stock does not pay dividends to its shareholders.
What is the beta indicator for Haemonetics?
Haemonetics (HAE) has a beta rating of 0.32. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.